BRAIN Biotech AG Company Presentation: Key Takeaways
BRAIN Biotech AG Company Presentation
In this Company Presentation on seat11a, Michael Schneiders, CFO of BRAIN Biotech AG, presents the company’s business model, biotechnology platform, growth opportunities and long-term strategy to become one of the world’s leading specialty enzyme companies.
Industrial Biotechnology and Specialty Enzyme Solutions
BRAIN Biotech is an industrial biotechnology company developing specialty enzymes, microorganisms and biological solutions for applications across food, life sciences and industrial markets. The company uses cells, microorganisms and biomolecules to develop biological processes that can operate under milder conditions, use renewable raw materials and reduce waste and emissions compared with conventional industrial processes.
BRAINBiocatalysts and BRAINBioIncubator
The company operates through two complementary pillars. BRAINBiocatalysts comprises the core specialty enzyme business, while BRAINBioIncubator contains selected high-innovation projects and participations with additional commercialisation potential. In FY 2024/25, BRAIN generated approximately €45.4 million in annual revenue and €4.4 million in adjusted EBITDA, complemented by approximately €4.2 million of recurring revenues.
Integrated Enzyme Value Chain and Biotechnology Platform
A key strength is BRAIN’s position across the entire enzyme value chain. Its capabilities extend from biological discovery, protein engineering and microbial strain development through fermentation, scale-up and industrial production to formulation, sales and distribution. BRAIN combines these capabilities across three business models: proprietary enzyme products and ingredients, contract research and contract manufacturing. This integrated structure enables the company to provide customised biological solutions while developing long-term relationships with industrial customers.
Global Industrial Enzyme Market and Growth Opportunities
The market opportunity is substantial. BRAIN estimates that the global market for industrial enzyme applications will expand by around 6–7% annually through 2030/2035, supported by structural trends including sustainability, resilience, changing food consumption and new pharmaceutical applications. Within BRAINBiocatalysts alone, management identifies more than €2 billion in accessible enzyme markets across applications including dairy, baking, brewing, fruit juice and wine, starch processing, life sciences and other specialties. Current BRAIN market shares remain mostly in the single digits, providing significant room for expansion.
BRAINBioIncubator and Biotechnology Innovation Projects
The second pillar, BRAINBioIncubator, provides additional value creation opportunities from breakthrough biotechnology projects. Its portfolio spans areas including fermented food and beverages, biological gold recovery, natural antimicrobials, chronic wound treatment, genome-editing technologies and pharmaceutical royalties. Management is increasingly partnering these projects with specialised external companies to share development costs, reduce risk and accelerate commercialisation.
▶️ Other videos:
Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/
Company Presentation: https://seat11a.com/investor-relations-company-presentation/
Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/
Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/
ESG Presentation: https://seat11a.com/investor-relations-esg/
T&C
This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.
